EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY 4.0

No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials

Charlotte Hedskog, Christoph D Spinner iD, Ulrike Protzer iD, Dieter Hoffmann, Chunkyu Ko iD, Robert L Gottlieb iD, Medhat Askar, Meta Roestenberg iD, Jutte J C de Vries iD, Ellen C Carbo, Ross Martin, Jiani Li und 15 weitere

Viruses · 31.03.2024 · 16 (4) · 546

DOI: 10.3390/v16040546 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Viruses, online erschienen am 31.03.2024. Verfasst von Charlotte Hedskog und 26 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc., Foster City, CA 94404, USA. Hauptthemen laut MEDLINE: Alanine, Adenosine Monophosphate, SARS-CoV-2, Antiviral Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, Gilead Sciences (United States).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Remdesivir (RDV) is a broad-spectrum nucleotide analog prodrug approved for the treatment of COVID-19 in hospitalized and non-hospitalized patients with clinical benefit demonstrated in multiple Phase 3 trials. Here we present SARS-CoV-2 resistance analyses from the Phase 3 SIMPLE clinical studies evaluating RDV in hospitalized participants with severe or moderate COVID-19 disease. The severe and moderate studies enrolled participants with radiologic evidence of pneumonia and a room-air oxygen saturation of ≤94% or >94%, respectively. Virology sample collection was optional in the study protocols. Sequencing and related viral load data were obtained retrospectively from participants at a subset of study sites with local sequencing capabilities (10 of 183 sites) at timepoints with detectable viral load. Among participants with both baseline and post-baseline sequencing data treated with RDV, emergent Nsp12 substitutions were observed in 4 of 19 (21%) participants in the severe study and none of the 2 participants in the moderate study. The following 5 substitutions emerged: T76I, A526V, A554V, E665K, and C697F. The substitutions T76I, A526V, A554V, and C697F had an EC50 fold change of ≤1.5 relative to the wildtype reference using a SARS-CoV-2 subgenomic replicon system, indicating no significant change in the susceptibility to RDV. The phenotyping of E665K could not be determined due to a lack of replication. These data reveal no evidence of relevant resistance emergence and further confirm the established efficacy profile of RDV with a high resistance barrier in COVID-19 patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlanineAdenosine MonophosphateSARS-CoV-2Antiviral AgentsCOVID-19 Drug TreatmentDrug Resistance, ViralViral LoadCOVID-19HumansMaleFemaleRetrospective StudiesMiddle AgedSeverity of Illness Index

Stichwörter der Autor:innen

Nsp12SARS-CoV-2genotypingphenotypingremdesivirresistance

Substanzen

remdesivirAlanineAdenosine MonophosphateAntiviral Agents

Autor:innen und Institutionen

  • Gilead Sciences, Inc., Foster City, CA 94404, USA.
  • TUM School of Medicine and Health, Department of Clinical Medicine-Clinical Department for Internal Medicine II, University Medical Center, Technical University of Munich, 81675 Munich, Germany.
  • German Center for Infection Research (DZIF), Munich Partner Site, 81675 Munich, Germany.
  • Institute of Virology, Technical University of Munich School of Medicine, 81675 Munich, Germany.
  • Institute of Virology, Helmholtz Munich, 85764 Munich, Germany.
  • Infectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Republic of Korea.

ORCID-Profile: Christoph D Spinner, Ulrike Protzer, Chunkyu Ko, Robert L Gottlieb, Meta Roestenberg, Jutte J C de Vries, Jason K Perry, Andrés Antón, Vanessa Casares, Huldrych F Günthard, Michael Huber, Navid Sadri, Judith A Aberg

Förderung

  • NCATS NIH HHS
  • Gilead Sciences (United States)

Zitieren

APA

Hedskog, C., Spinner, C. D., Protzer, U., Hoffmann, D., Ko, C., Gottlieb, R. L., Askar, M., Roestenberg, M., de Vries, J. J. C., Carbo, E. C., Martin, R., Li, J., Han, D., Rodriguez, L., Parvangada, A., Perry, J. K., Ferrer, R., Antón, A., Andrés, C., …, & Porter, D. P. (2024). No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials. Viruses, 16(4), 546. https://doi.org/10.3390/v16040546

Vancouver

Hedskog C, Spinner CD, Protzer U, Hoffmann D, Ko C, Gottlieb RL, et al. No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials. Viruses. 2024;16(4):546. doi:10.3390/v16040546

BibTeX
@article{Hedskog2024,
  author = {Hedskog, Charlotte and Spinner, Christoph D and Protzer, Ulrike and Hoffmann, Dieter and Ko, Chunkyu and Gottlieb, Robert L and Askar, Medhat and Roestenberg, Meta and de Vries, Jutte J C and Carbo, Ellen C and Martin, Ross and Li, Jiani and Han, Dong and Rodriguez, Lauren and Parvangada, Aiyappa and Perry, Jason K and Ferrer, Ricard and Antón, Andrés and Andrés, Cristina and Casares, Vanessa and Günthard, Huldrych F and Huber, Michael and McComsey, Grace A and Sadri, Navid and Aberg, Judith A and van Bakel, Harm and Porter, Danielle P},
  title = {No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials},
  journal = {Viruses},
  year = {2024},
  volume = {16},
  number = {4},
  pages = {546},
  doi = {10.3390/v16040546}
}
Kostenlos starten →